 ISSN: **3107-6513**

Tumor Lysis Syndrome: Narrative Review of Risk Stratification and Management

Venkatesh [1], Shivani Venkatesh[2], Oshina Ugrani Manoj Kumar[2], Meghana Narayana[2], Abhilash Gollarahalli Hanumanthappa[3], Sheba Baby John*[2], Maniraj[3], Charan Chabbanahalli Somashekhar[2], Hanumanthachar Joshi[4]

[1]Department of Pharmaceutics, Sarada Vilas College of Pharmacy, Mysuru.
[2]Department of Pharmacy Practice, Sarada Vilas College of Pharmacy, Mysuru.
[3]Bharath hospital and institute of oncology, Mysuru.
[4]Department of Pharmacognosy, Sarada Vilas College of Pharmacy, Mysuru.
shebabjohn7@gmail.com, oshina182002@gmail.com, shiavniv2002@gmail.com

Abstract:

The quick death of cancer cells causes tumor lysis syndrome (TLS), a life-threatening oncologic emergency that results in the release of intracellular components like potassium. nucleic acids and phosphate into the systemic circulation. Hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia are all produced by this cascade, and if they are not identified and treated right away, they can lead to arrhythmias, seizures, acute kidney injury, and even death. This review synthesizes data from PubMed, Embase, Web of Science, and the Cochrane Library, concentrating on clinical studies, randomized trials, retrospective analyses, and meta-analyses that were published between 2000 and 2025. According to research, the risk of TLS depends on the kind of tumor, the patient's profile, and the course of therapy. Rasburicase has consistently demonstrated superiority over allopurinol among pharmacological treatments for quickly lowering uric acid in adults and children, particularly in those at high risk. Febuxostat has proven non-inferior to allopurinol, making it a viable option when allopurinol is contraindicated. Cost-effective approaches, such as single-dose rasburicase protocols, have become popular in resource-constrained environments. Rasburicase is the preferred treatment for high-risk instances, while allopurinol and febuxostat are still suitable for patients with low-to intermediate risk. Ultimately, accurate risk stratification, early intervention, And increasing the availability of successful treatments is still essential for lowering the incidence and death associated with TLS.

Keywords: Tumor Lysis Syndrome, Risk Stratification, Rasburicase, Allopurinol, Febuxostat, Prophylaxis, Acute Kidney Injury

1. Introduction

Tumor lysis syndrome (TLS) is a fatal oncological emergency caused by the fast destruction of cancer cells either naturally or more usually after the Initiation of cytotoxic therapy. The great release of intracellular contents like as potassium, phosphate, and nucleic acids overpowers normal homeostatic processes and sets off a cascade including hyperkalemia, hyperphosphatemia, secondary hypocalcemia, and hyperuricemiaThese metabolic anomalies can cause acute kidney injury, cardiac arrhythmias, seizures, and sudden death unrecognized or improperly treated (2)

Though TLS was first reported in highly proliferative hematologic malignancies, notably Burkitt lymphoma and acute lymphoblastic leukemia (ALL), its scope has grown to encompass solid tumors, especially those with high tumor load and chemosensitivity like small-cell lung cancer and hepatocellular carcinoma (3). The growing frequency of TLS in solid tumors is explained by the more intense chemotherapy regimens and focused medicines, which could cause rapid tumor cytoreduction.

The Cairo–Bishop criteria (2004) divided TLS diagnosis: laboratory TLS, characterized by biochemical evidence of uric acid, potassium,

phosphate, and calcium abnormalities; and clinical TLS, which combines lab TLS with symptoms including renal failure, convulsions, or cardiac arrhythmias (3). Enabling more consistent recognition and reporting of TLS, this categorization has come to be used in clinical studies as well as in clinical practice.

TLS still has a lot of morbidity and mortality even with improvements in supportive care. Its clinical effects go beyond the initial emergency since it might postpone or change anti-cancer treatment, therefore jeopardizing long-term results (1). Early identification, precise risk Effective TLS management depends on stratification and suitable prophylaxis; these two pillars of this approach remain fundamental. Over the last two decades, especially rasburicase, new pharmacological compounds have been created with shown superiority over allopurinol in high-risk patients and febuxostat. In moderate-risk situations, one possible substitute for allopurinol has surfaced.

This study seeks to present a comprehensive synthesis of first clinical findings published between 2000 and 2025 with a focus on risk. Models for stratification, preventative measures, and the relative efficacy of pharmacological therapies in TLS include data from adult and pediatric populations, hematological and solid tumors, by highlighting current best practices, this review aims to identify research topics for the future.

2. Methodology

2.1 Study Design

The study was conducted as a sequential narrative review focused only on original clinical research. The review aimed to analyse evidence regarding the risk stratification, prevention and treatment of tumour lysis syndrome (TLS) from the original clinical trial data, notably urate-lowering therapies rasburicase, allopurinol and febuxostat.

2.2 Literature-search strategy

The literature was searched for publications in PubMed/MEDLINE entries, Embase, Web of Science, and the Cochrane Library published between January 2000 and May 2025. The search terms included Medical Subject Heads (MeSH) and free-text terms: “tumour lysis syndrome”,”TLS”,”risk stratification”,”management”,”prevention”,”rasburicase”,”allopurinol” and “febuxostat.” By using Boolean operators (AND, OR), and filters, combinations limited to human studies, English language, and the defined date searches were used.

2.3 Inclusion Criteria

Studies were acceptable as long as they met the following criteria:

1. Original clinical research studies reporting on forward or backward cohorts, random controls, or meta-analyses based on actual data sets.
2. Diagnosed with tumour lysis syndrome or could be diagnosed with tumour lysis syndrome, adults or children with established metastatic or haematological malignancies.
3. Included outcomes related to renal outcomes (dialysis, acute kidney injury), survival, clinical incidence of TLS, biological results (calcium, potassium, phosphate, uric acid), or health careoutput

2.4 Exclusion Criteria

The following studies were left out:

1. Articles like case reports, case series, editorials, and expert opinions that don't contain primary data.
2. Work published in languages other than English.
3. Pre-2000 studies are still relevant to oncology today.
4. Preclinical or animal studies.

2.5 Study Selection and Data Extraction

Numerous citations were found in the first search, these were filtered by abstract and title. Full texts of studies that might be eligible were retrieved after duplicates were eliminated. The most thorough or recent study was included to resolve overlapping datasets after articles were carefully examined for eligibility.

A structured form was used to extract the data, documenting:

- Patient characteristics and type of malignancy
- Study design and publication year
- Primary and secondary results (biochemical correction, incidence of TLS, renal outcomes, hospitalization, cost, and mortality)

• Intervention (dosage and regimen of rasburicase, allopurinol, or febuxostat) and Comparator

2.6 Data Synthesis

Considering the narrative character of this review, results were thematically grouped and summarized qualitatively rather than being statistically combined:

1. TLS classification and pathophysiology
2. Methods of risk stratification
3. Preventative strategies and medical prophylaxis
4. Relative effectiveness of febuxostat, allopurinol, and rasburicase

Fresh information and clinical problems

This systematic technique ensured the review properly reflected the clinical efficacy of current oncology practice as well as the realistic elements including dose schedules of TLS management and cost-effectiveness.

3. Results

3.1 Pathophysiology and Classification

The quick release of intracellular metabolites from cancer cells causes TLS to arise. Metabolized into uric acid, which is poorly soluble and prone to crystalizing within renal tubules, nucleic acids released into the bloodstream cause acute kidney damage? At the same time, phosphate release causes hyperphosphatemia and subsequent calcium–phosphate precipitation, which shows as hypocalcemia, while potassium efflux from tumor cells results in hyperkalemia, which can cause fatal arrhythmias. The biochemical profile of TLS (2) is produced by all of these derangements.

The Cairo–Bishop classification separates TLS into laboratory TLS, defined by ≥25% change or threshold abnormality in two or more biochemical indicators, and clinical TLS, Complications including renal failure, seizures, or cardiac dysrhythmias accompany some lab changes (3). For both clinical trials and bedside diagnosis, this definition still serves as the base.

3.2 Risk Stratification

Proper risk stratification is essential for directing proactive measures. Defining risk are three main categories: tumor-specific, patient-specific, and therapy-related components. Among high-risk hematological malignancies are Burkitt lymphoma, high leukocyte-count acute lymphoblastic leukemia, and other fast-spreading malignancies with great chemosensitivity. The probability of TLS raises even more when patient features include as dehydration, elevated lactate dehydrogenase (LDH), and baseline renal insufficiency. Treatment factors include the use of corticosteroids, high-intensity chemotherapy, or novel targeted therapies also influence risk.

These criteria help patients to be grouped into low, moderate, or high risk categories. Low-risk patients usually need observation and hydration; intermediate-risk patients need hydration plus uric acid–lowering treatment such allopurinol or febuxostat; and high-risk patients call for hydration plus rasburicase (2).(**Table.1).**

Table.1. Risk Stratification and Management of TLS

Risk Category	**Defining Features**	**Prophylaxis / Management**	**Preferred Drug**
Low Risk	Indolent tumors, low tumor burden, normal renal function	Observation + IV hydration	None / Allopurinol (if mild risk)
Intermediate Risk	Moderate tumor burden, some risk factors (↑LDH, borderline renal function)	IV hydration + uric acid–lowering agent	Allopurinol or Febuxostat
High Risk	Burkitt lymphoma, ALL with high WBC, bulky chemosensitive tumors, renal impairment	Aggressive IV hydration + uric acid–lowering agent	Rasburicase

3.3 Pharmacological Management

Table.2. Comparative Pharmacological Profile of TLS Drugs

Drug	Mechanism	Onset of Action	Strengths	Limitations	Best Use Case
Allopurinol	Xanthine oxidase inhibitor → prevents new uric acid formation	Slow (24–72 hrs)	Widely available, cheap	Cannot reduce existing uric acid, risk of xanthine accumulation	Low–Intermediate risk TLS
Rasburicase	Recombinant urate oxidase → converts uric acid → allantoin	Rapid (≤4 hrs)	Fast, effective, prevents AKI, reduces hospital stay	Expensive, contraindicated in G6PD deficiency	High-risk TLS (adult & pediatric)
Febuxostat	Non-purine xanthine oxidase inhibitor	Intermediate (12–24 hrs)	Non-inferior to allopurinol, safe in allopurinol allergy	Limited data in high-risk TLS, costlier than allopurinol	Alternative in Intermediate risk or Allopurinol intolerance

3.3.1 Allopurinol

By preventing the formation of new uric acid, xanthine oxidase inhibitor allopurinol inhibits purine metabolism. It has long been the standard agent for TLS prophylaxis in low- to intermediate-risk patients. But its inability to lower current uric acid and its possibility for xanthine buildup restrict its utility in high-risk situations (4).

3.3.2 Rasburicase

Directly metabolizing uric acid into allantoin, which is five to ten times more soluble and easily excreted, is rasburicase, a recombinant urate oxidase enzyme. Its advantage over allopurinol has been proven by several experiments. Cortes et al. (2010) found in a major multicenter phase III randomized trial that rasburicase provided uric acid regulation in 87% of adult patients when compared with at 66%, with allopurinol, with a significantly faster onset of action (4 hours vs 27 hours)(1). Likewise, a demonstration of pediatric RCT showed that rasburicase decreased uric acid area under the curve more than twice as compared to allopurinol, therefore lowering the risk of renal problems (4).

Apart from efficiency, rasburicase showed financial benefits. Compared to those receiving allopurinol (5), patients treated with rasburicase showed shorter ICU stays and lower total hospitalization costs according Cairo et al. (2012). Significantly, studies have proved that single fixed-dose regimes save money as well as work effectively. With repeat dosing necessary just in a small proportion of cases (6), Vadhan-Raj et al. (2009) verified that a single dose in the majority of adults normalized uric acid levels. (**Table.2**).

3.3.3 Febuxostat

Alternative to allopurinol, Febuxostat, a non-purine selective xanthine oxidase inhibitor, has developed. FEBuxostat showed non-inferiority to

 ISSN: 3107-6513

allopurinol in stopping TLS among patients with hematologic malignancies (7) in a phase III study by Kuwabara et al. (2016). Retrospective Including Ichida et al. (2014), studies further verified similar decreases in uric acid levels with no notable variance in TLS incidence (8). A meta-analysis by 6 studies with 658 patients were combined by Yan et al. (2019) to highlight the non-inferiority of febuxostat to allopurinol, making it a possible prophylactic choice especially in patients intolerant of allopurinol (9). **(Fig.1).**



Fig.1 Comparative effectiveness of TLS pharmacological agents

4. Discussion

4.1 Importance of Risk Stratification

Finding patients at highest risk is the basis of TLS management. Because of their quick spread and high chemosensitivity (2), patient-related factors including preexisting renal impairment, high lactate dehydrogenase (LDH), and dehydration further elevate vulnerability (3). Treatment-related issues include the use furthermore elevating the risk profile are corticosteroids or intense multi-agent chemotherapy. Consequently, directing strong treatments like rasburicase toward high-risk patients helps to guide prophylactic strategies by stratifying into low, intermediate, and high-risk groups. Reserving allopurinol or observation for lower-risk groups helps doctors to avoid excessive treatment while avoiding mortality in at-risk patients.

4.2 Role of Supportive Care Measures

Still fundamentals of TLS prevention across all risk groups are hydration and thorough monitoring. Proper intravenous fluid management improves renal perfusion and helps uric acid and electrolytes to be excreted. Early detection of electrolyte abnormalities is made possible by regular laboratory monitoring, especially in high-risk individuals, therefore preventing organ failure (2). Though once advised, urine alkalinization's advantages are debatable owing to the possible risk of calcium–phosphate precipitation in renal tubules. Most environments now favor hydration without alkalinization.

4.3 Efficacy of Rasburicase

For high-risk individuals, rasburicase always shows to be the most potent urate-lowering medication. In a phase III randomized trial, Cortes et al. (2010) showed that, as opposed with 66% for allopurinol, rasburicase normalized uric acid in 87% of adults having a median time to control of just 4 hours (1). Pui et al. (2001) found a 2.6-fold decrease in uric acid exposure in pediatric populations with rasburicase compared to allopurinol, hence lowering the frequency of Beyond effectiveness, rasburicase also enhances

healthcare outcomes; a retrospective study by Cairo et al. (2012) showed shorter ICU stays and lower hospital Costs in patients on rasburicase versus those on allopurinol (5). Significantly more cost-effective than conventional multi-day dosing, single-dose rasburicase regimens are also effective in most people, according to studies such Vadhan-Raj et al. (2009) (6).

4.4 Limitations of Allopurinol

Although inexpensive and readily available, allopurinol has a mechanism of action that limits its utility. While it prevents the formation of new uric acid by blocking the enzyme xanthine oxidase, it does not lower any currently existing uric acid levels. This delay in action is clinically relevant, particularly in patients with substantial elevations in uric acid levels, as they may, from time to time, require urgent treatment to prevent kidney damage (2). In addition, there is concern that allopurinol may increase xanthine levels, which itself may crystallize within renal tubules. So while allopurinol is still appropriate for low- and medium-risk patients, its potential usage to treat high-risk situations cannot be compared to rasburicase.

4.5 The Rising Role of Febuxostat

Febuxostat, especially beneficial in patients who are allergic to or intolerant of allopurinol, is gaining traction as an alternative xanthine oxidase inhibitor. In a phase III randomized trial, Kuwabara et al. (2016) demonstrated that febuxostat was non-inferior to allopurinol with respect to TLS prevention for patients with hematological malignancies (7). Similarly, a retrospective analysis by Ichida et al. (2014) supported a similar reduction in uric acid levels when comparing febuxostat and allopurinol with no significant differences in TLS rate (8). A meta-analysis of six studies by Yan et al. (2019) has further corroborated that febuxostat is non-inferior to allopurinol with a comparable safety profile (9).Although febuxostat is improbable to replace rasburicase in high-risk circumstances, it does provide a useful choice for those with intermediate-risk or if allopurinol is contraindicated.

4.6 Clinical Issues and future directions

Despite new advances, many issues remain. It is still often overlooked that reasons for delayed detection and treatment of TLS in solid tumors come from the unreasonable burden of the disease state TLS also brings. Below are some of the elements that lead to inadequate treatment too many patients. Furthermore, even in patients with high-risk factors, the expense of Rasburicase limits treatment and it also excludes so many low- and middle-income countries from access to it. In addition to this problem, there are not yet adequate prognostications to predict TLS to be achieved a priori; the current stratifications are based on clinical and laboratory parameters and are not meeting the needs of recognizing TLS in early stages Overly reliance on accepted laboratory values contributes to missing subtle early clues.

Future work should focus on accurate predictive algorithms inclusive of molecular markers, operationalizing affordable rasburicase dosing protocols such as utilizing the fixed low-dose regimen, and broader comparative Febuxostat reviews at various demographic levels. Electronic Monitoring combined with electronic health records and decision-support systems could enhance early detection/delivery of rapid treatment to TLS.

5. Conclusion

Currently, TLS remains a serious issue in modern oncology. Future action to lessen the associated morbidity and mortality of TLS still depends too much on the timely detection of TLS, proper risk stratification, and acting in an appropriate prophylactic manner. While febuxostat and allopurinol are appropriate treatments in lower-risk settings, rasburicase is the only drug that can also effectively lower urate levels in patients at highest risk for TLS. Future studies should work to enhance the ability to accurately predict TLS, validate biomarkers, and enhance access to affordable rasburicase dosing guidelines particularly in countries with shared low socioeconomic healthcare.

6. References

[1] J. Cortes, *et al.*, "Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—a multicenter phase III study," *J. Clin. Oncol.*, vol. 28, no. 27, pp. 4207–4213, 2010.

[2] S. C. Howard, D. P. Jones, and C. H. Pui, "The tumor lysis syndrome," *N. Engl. J. Med.*, vol. 364, no. 19, pp. 1844–1854, 2011.

[3] M. S. Cairo and M. Bishop, "Tumour lysis syndrome: new therapeutic strategies and classification," *Br. J. Haematol.*, vol. 127, no. 1, pp. 3–11, 2004.

[4] C. H. Pui, *et al.*, "Rasburicase versus allopurinol in children with hyperuricemia and malignancy: results of a randomized, controlled trial," *Blood*, vol. 97, no. 10, pp. 2998–3003, 2001.

[5] M. S. Cairo, *et al.*, "Costs and outcomes associated with rasburicase versus allopurinol in patients with tumor lysis syndrome," *Blood*, vol. 120, no. 21, p. 3175, 2012.

[6] S. Vadhan-Raj, *et al.*, "Randomized clinical trial of rasburicase: single dose versus daily administration in adults at risk for tumor lysis syndrome," *Blood*, vol. 114, no. 22, p. 105, 2009.

[7] M. Kuwabara, *et al.*, "Efficacy and safety of febuxostat compared with allopurinol for the prevention of tumor lysis syndrome in patients with hematologic malignancies: a phase III, randomized, multicenter trial," *Int. J. Hematol.*, vol. 103, no. 2, pp. 262–270, 2016.

[8] K. Ichida, *et al.*, "Hypouricemic effect and safety of febuxostat for prevention of tumor lysis syndrome: a retrospective cohort study," *Int. J. Hematol.*, vol. 100, no. 6, pp. 593–600, 2014.

[9] X. Yan, *et al.*, "Febuxostat administration for the prevention of tumor lysis syndrome: a meta-analysis," *Hematol. Oncol.*, vol. 37, no. 2, pp. 132–140, 2019.